{
    "clinical_study": {
        "@rank": "51833", 
        "arm_group": {
            "arm_group_label": "Questionnaires", 
            "description": "No treatment"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the prevalence of geriatric syndromes in older adults with multiple\n      myeloma, examine relationships between baseline geriatrics syndromes and initial treatment\n      selection, and examine risk of functional decline.\n\n      Relationship between baseline geriatric questionnaires and initial treatment selection in\n      older adults with newly diagnosed multiple myeloma.\n\n      Feasibility of subjects completing the CARG geriatric assessments at baseline, 3 months and\n      6 months.\n\n      Comorbidities or dependence in IADLs at baseline predict decline in functional status at 6\n      months of follow-up in older adults with newly diagnosed multiple myeloma."
        }, 
        "brief_title": "Geriatric Assessments in Senior Adults With Multiple Myeloma", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must have a diagnosis of multiple myeloma by IMWF criteria: diagnosis must\n             have occurred within 3 months of study enrollment.\n\n          -  Patient must be \u2265 65 years of age.\n\n          -  Patient's life expectancy must be \u2265 6 months.\n\n          -  Patient must be willing to complete follow-up assessments.\n\n          -  Patient must be able to understand and willing to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Patient must not have a diagnosis of smoldering myeloma.\n\n          -  Patient must not have concomitant amyloidosis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Bone Marrow Transplant Clinic at Siteman Cancer Center"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746030", 
            "org_study_id": "201207060"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 5, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": [
            {
                "contact": {
                    "email": "twildes@dom.wustl.edu", 
                    "last_name": "Tanya Wildes, M.D.", 
                    "phone": "314-362-5654"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": [
                    {
                        "last_name": "Camille Abboud, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Kenneth Carson, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Amanda Cashen, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "John DiPersio, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Keith Stockerl-Goldstein, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Geoffrey Uy, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ravi Vij, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Peter Westervelt, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Tanya Wildes, M.D.", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sascha.tuchman@duke.edu", 
                    "last_name": "Sascha Tuchman, M.D.", 
                    "phone": "919-668-1011"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University"
                }, 
                "investigator": {
                    "last_name": "Sascha Tuchman, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Pilot Study of Geriatric Assessments in Senior Adults With Multiple Myeloma", 
        "overall_contact": {
            "email": "twildes@dom.wustl.edu", 
            "last_name": "Tanya Wildes, M.D.", 
            "phone": "314-362-5654"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Tanya Wildes, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The physician caring for the patient will be asked to identify his/her initial treatment recommendations.  This includes whether the patient is, in his/her assessment, a candidate for high dose therapy and autologous stem cell transplantation.  It will also include whether a 2-drug or 3-drug regimen is recommended initially.", 
            "measure": "The relationship between initial treatment recommendation and baseline questionnaires assessment", 
            "safety_issue": "No", 
            "time_frame": "At baseline visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746030"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Logistic regression analyses, adjusted odds ratios (ORs) based on model will be given with 95% CIs. All analyses will use two-tailed significance levels of 0.05 and will be conducted with statistical software SAS 9.2. Geriatric assessment variables will be analyzed as continuous or ordinal variables as indicated. Candidate variables will include: demographic data (including age, gender, race), disease data (stage, cytogenetic abnormalities), or geriatric assessment variables (comorbidity, functional status, physical function, psychological state, nutrition, social support and social activity). Analyses will be performed for the outcomes of treatment selection (transplant vs non-transplant) and increased dependence in IADLs", 
                "measure": "Changes in questionnaires from baseline to 6 months", 
                "safety_issue": "No", 
                "time_frame": "Through 6 months of follow-up"
            }, 
            {
                "description": "Feasibility of subjects completing questionnaires is defined as 90% of consenting subjects completing the baseline geriatric assessment battery, and 80% of consenting subjects completing follow-up assessments at 3 and 6 months.", 
                "measure": "Completion of the questionnaires at baseline, 3 months and 6 months.", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 months, and 6 months"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}